HR Execs on the Move


 
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.amylyx.com
  • 43 Thorndike Street
    Cambridge, MA USA 02141
  • Phone: 617.682.0917

Executives

Name Title Contact Details
Martin Mitchell
Head of Global Talent Attraction Profile
Doreen Nichols
Head of Talent and HR Business Partnering Profile
Linda Arsenault
Chief Human Resources Officer Profile

Similar Companies

Greater Nashua Mental Health

Greater Nashua Mental Health believes in empowering people to lead full and satisfying lives through effective treatment and support.

FamilyServiceRV

#Mentalhealth causes invisible wounds. Find strength, hope and how you can help heal others. Family Service of Roanoke Valley. https://t.co/57fyeIBthG

Direct Success

Direct Success is a Wall Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

genetic Immunity

genetic Immunity is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.